Acute Respiratory Distress Network (ARDSNet) Study 02 Late Steroid Rescue Study (LaSRS) - Catalog

  • Name

    Acute Respiratory Distress Network (ARDSNet) Study 02 Late Steroid Rescue Study (LaSRS)

  • Accession Number

    HLB00660808a

  • Acronym

    ARDSNet-LaSRS

  • Related studies
  • BSI Study IDs

    AR2

  • Is public use dataset

    False

  • Keywords
  • Ingestion Status
    Released
  • Has Study Datasets

    True

  • Has Specimens

    True

  • Specimen ID Type
    Coded
  • Study Website

    http://www.ardsnet.org/

  • The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

    False

  • Clinical Trial URLs
    NCT00000579
  • Study type
    Clinical Trial
  • Collection Type
    Open BioLINCC Study
  • Cohort type
    Both
  • Interventions

    Procedure: Low Tidal Volume VentilationProcedure: Positive End-Expiratory PressureDrug: LysofyllineDrug: MethylprednisoloneDrug: KetoconazoleProcedure: Fluid ManagementProcedure: Pulmonary Artery Catheter

  • Study Open Date (Data)

    2009-10-01

  • Study Open Date (Specimens)

    2010-04-09

  • Date materials available

    2008-10-13

  • Last updated

    2006-08-24

  • Study period

    1997-2003

  • Study Contacts
  • NHLBI Division

    DLD

  • Classification
    Lung
  • HIV study classification
    non-HIV
  • COVID study classification
    non-COVID
  • Pre-Website # of Specimens Shipped

    4183

  • # of Returned Specimens

    0

  • Primary Publication URLs
    16625008
  • Commercial use data restrictions
    No
  • Data restrictions based on area of research
    No
  • Commercial use specimen restrictions
    No
  • Non-genetic use specimen restrictions based on area of use
    No
  • Genetic use of specimens allowed?
    Yes, For Some Specimens
  • Genetic use area of research restrictions
    No
  • Specific Consent Restrictions
  • Conditions
    ALI
    ARDS
    Acute Lung Injury
    Lung Diseases
    Respiratory Distress Syndrome, Adult
  • Objectives

    Since previous reports suggested that corticosteroids may improve survival, this project was developed as a multicenter, randomized controlled trial of corticosteroids in patients with persistent ARDS.

  • Background

    Persistent acute respiratory distress syndrome (ARDS) is characterized by excessive fibroproliferation, ongoing inflammation, prolonged mechanical ventilation, and a substantial risk of death.

  • Participants

    180 randomly assigned patients with ARDS of at least seven days duration received either methylprednisolone or placebo in a double-blind fashion. The primary end point was mortality at 60 days.

  • Design
  • Conclusions

    The results do not support the routine use of methylprednisolone for persistent ARDS despite the improvement in cardiopulmonary physiology. In addition, starting methylprednisolone therapy more than two weeks after the onset of ARDS may increase the risk of death. (NEJM April 20, 2006; Vol 354, No. 16, pp 1671-84)

  • Disease classification
  • Publications
  • Mat types
    BAL Slides
    Bronchial Lavage
    Plasma
  • Network
    Acute Respiratory Distress Network (ARDSNet)

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    Placebo: 91

    Methylprednisolone: 89


    Last Modified: Jan. 6, 2026, 12:08 p.m.
  • Age

     

    Placebo

    Methylprednisolone

    Total Subjects

    < 30

    11

    14

    25

    30-39

    16

    19

    35

    40-49

    18

    16

    34

    50-59

    23

    13

    36

    60-69

    11

    11

    22

    70+

    12

    16

    28


    Last Modified: Jan. 6, 2026, 12:08 p.m.
  • Sex

     

    Placebo

    Methylprednisolone

    Total Subjects

    Female

    53

    36

    89

    Male

    38

    53

    91


    Last Modified: Jan. 6, 2026, 12:08 p.m.
  • Race

     

    Placebo

    Methylprednisolone

    Total Subjects

    White non-Hispanic

    72

    59

    131

    Black non-Hispanic

    9

    19

    28

    Other

    10

    11

    21


    Last Modified: Jan. 6, 2026, 12:08 p.m.

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. The BioLINCC Users Guide describes the components of the review process.

  • Material Types

    Plasma, Bronchoalveolar Lavage (BAL), BAL Slide


    Last Modified: Jan. 6, 2026, 12:05 p.m.
  • General Freeze/Thaw Status

    Plasma: Majority unthawed

    BAL: Majority 1 thaw

    BAL Slides: Unthawed


    Last Modified: Jan. 6, 2026, 12:05 p.m.
  • Visits (Vials)

    01/06/2026

     

    Plasma

    Bronchoalveolar Lavage (BAL)

    BAL Slide

    Total Vials

    Day 0

    85

    1,837

    330

    2,252

    Day 7

    75

    1,351

    221

    1,647


    Last Modified: Jan. 6, 2026, 12:05 p.m.
  • Visits (Subjects)

    01/06/2026

     

     

    Plasma

    Total number of subjects

    Average volume (mL) per subject

    Day 0

    14

    5.47

    Day 7

    13

    5.78

     

     

    Bronchoalveolar Lavage (BAL)

    Total number of subjects

    Average volume (uL) per subject

    Day 0

    86

    28.34

    Day 7

    64

    28.26

     

     

    BAL Slide

    Total number of subjects

    Average vials per subject

    Day 0

    74

    4.46

    Day 7

    54

    4.09


    Last Modified: Jan. 6, 2026, 12:05 p.m.